CALGARY, ALBERTA--(Marketwired - Nov. 2, 2016) -
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.
Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM)(OTCQB:HMTXF) - Dr. Elmar Burchardt, President and Chief Executive Officer of Hemostemix, reports that Lyle Wunderlich ("Mr. Wunderlich"), who previously acquired ownership of a $1M convertible debenture and $180,000 convertible promissory note on September 2, 2016 (collectively referred to as the "Convertible Securities"), has filed an early warning report in accordance with National Instrument 62-103. The terms of the Convertible Securities were previously disclosed in the Company's news release issued on September 2, 2016.
As a result of the acquisition of the Convertible Securities, and assuming conversion in full and exercise of the underlying warrants, Mr. Wunderlich would hold 10,500,000 Common Shares, representing approximately 13.5% of the issued and outstanding Common Shares after giving effect to such conversion. Together with the 2,586,133 Common Shares previously acquired by Mr. Wunderlich, the acquisition of the Convertible Securities increases the total number of Common Shares owned or deemed to be owned by Mr. Wunderlich to 13,086,133, representing approximately 16.2% of the issued and outstanding common shares of the Company.
The securities acquired by Mr. Wunderlich are held for investment purposes. In the future, Mr. Wunderlich may increase or decrease his respective ownership of securities of the Company from time to time depending upon the business and future market conditions.
A copy of the early warning report filed pursuant to National Instrument 62-103 may be obtained on SEDAR.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.